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RESEARCH ARTICLE
Cul3 regulates cyclin E1 protein abundance via a degron located
within the N-terminal region of cyclin E
Brittney Davidge1,‡, Katia Graziella de Oliveira Rebola1, Larry N. Agbor2,*, Curt D. Sigmund2 and
Jeffrey D. Singer1,§
ABSTRACT
Cyclin E and its binding partner Cdk2 control the G1/S transition in
mammalian cells. Increased levels of cyclin E are found in
some cancers. Additionally, proteolytic removal of the cyclin E
N-terminus occurs in some cancers and is associated with
increased cyclin E–Cdk2 activity and poor clinical prognosis.
Cyclin E levels are tightly regulated and controlled in part through
ubiquitin-mediated degradation initiated by one of two E3 ligases,
Cul1 and Cul3. Cul1 ubiquitylates phosphorylated cyclin E, but the
mechanism through which Cul3 ubiquitylates cyclin E is poorly
understood. In experiments to ascertain how Cul3 mediates cyclin
E destruction, we identified a degron on cyclin E that Cul3 targets
for ubiquitylation. Recognition of the degron and binding of Cul3
does not require a BTB domain-containing adaptor protein.
Additionally, this degron is lacking in N-terminally truncated
cyclin E. Our results describe a mechanism whereby N-terminally
truncated cyclin E can avoid the Cul3-mediated degradation
pathway. This mechanism helps to explain the increased activity
that is associated with the truncated cyclin E variants that occurs in
some cancers.
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INTRODUCTION
Cyclin E and its binding partner Cdk2 regulate the transition from
G1 to S phase and release from quiescence in mammalian cells (Koff
et al., 1991; Geng et al., 2003). Thus, it is not surprising that cell
cycle errors are associated with alterations in cyclin E function and/
or abundance; fibroblasts lacking both cyclin E genes, cyclin E1 and
cyclin E2, are unable to exit from quiescence (Geng et al., 2003). In
contrast, overexpression of cyclin E is associated with cancer and
tumorigenesis (Said and Medina, 1995). Analysis of the cyclin E
protein has revealed several functional domains, including a central
cyclin homology domain, which interacts with Cdk2, a unique
N-terminal region, and a C-terminal PEST sequence (residues
385-401), which is commonly found in proteins that get degraded
through the ubiquitin system (Lew et al., 1991; Rogers and
Rechsteiner, 1986; Rogers et al., 1986; Richardson et al., 1993;
Honda et al., 2005; Rath and Senapati, 2014). In certain cancers,
including breast, ovarian and melanoma, cyclin E (50 kDa) is
known to be cleaved by proteases resulting in N-terminally
truncated low molecular mass (LMM) forms ranging in size from
33 to 45 kDa (Scuderi et al., 1996; Porter and Keyomarsi, 2000;
Porter et al., 2001; Harwell et al., 2000; Wang et al., 2003;
Libertini et al., 2005). LMM cyclin E activates Cdk2 and
demonstrates increased cyclin E–Cdk2 activity (Porter et al.,
2001). These forms of cyclin E are associated with poor clinical
prognosis in cancer patients (Porter et al., 2001; Harwell et al.,
2000; Duong et al., 2012).
Cyclin E expression is restricted to the G1/S transition by two
distinct E3 ubiquitin ligases, which are responsible for the
degradation of cyclin E: Cul1 and Cul3 (Clurman et al., 1996;
Singer et al., 1999; Strohmaier et al., 2001; Welcker et al., 2003).
Both Cul1 and Cul3 are members of the cullin-RING family of
ubiquitin ligases. Cul1 SCF-based (SCF denotes an Skp1, Cul1 and
F-box protein complex) ligases use Fbxw7 (as the F-box protein
component of the SCF complex) as a substrate adaptor to recognize
cyclin E (Strohmaier et al., 2001; Koepp et al., 2001; Hao et al.,
2007). Cul1 mediated-degradation requires phosphorylation of
cyclin E at T77 and T395 in order for ubiquitylation of cyclin E to
occur (Loeb et al., 2005; Welcker et al., 2003; Clurman et al., 1996;
Minella et al., 2008). Cul1-mediated degradation of cyclin E occurs
at ∼4 h following release from a thymidine block (S phase)
(Bhaskaran et al., 2013).
In contrast to the Cul1 pathway, the mechanistic details of Cul3-
mediated destruction of cyclin E remain largely uncharacterized.
Similar to Cul1 complexes, Cul3 ubiquitin ligase complexes
consist of a substrate adaptor [a ‘bric-a-brac; tramtrack, broad-
complex’ (BTB) domain-containing protein] that binds near the
Cul3 N-terminus to recruit substrates, and a C-terminal region that
binds to the RING finger protein Rbx1 (Tyers and Jorgensen, 2000;
Jin and Harper, 2002; Duda et al., 2008), which in turn, recruits an E2
ubiquitin-conjugating enzyme (Petroski and Deshaies, 2005).
Previous studies from our laboratory have shown that Cul3
degrades cyclin E that is not bound to Cdk2 and regulation of
cyclin E by Cul3 is necessary for the maintenance of quiescence in
the liver (Singer et al., 1999; McEvoy et al., 2007).
Despite the advances, many details regarding the mechanism
utilized by Cul3 for cyclin E ubiquitylation remain uncharacterized,
including the location of the degron that Cul3 uses to recognize and
ubiquitylate cyclin E. A degron is a sequence or structural motif that
is required for a protein to be recognized and degraded in a
ubiquitin-dependent manner and can include both the ubiquitylated
lysine residue as well as other features required for ubiquitylation,
such as a binding site (Laney and Hochstrasser, 1999). Here, we
identify the degron targeted by Cul3 near the N-terminus of cyclin E,
and a unique mechanism for Cul3-mediated cyclin E destruction
is proposed.Received 8 April 2019; Accepted 7 October 2019
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Cyclin E binds directly to Cul3 independently of BTB domain-
containing proteins
Cul3 has been shown to require a BTB domain-containing protein to
bind substrates (Pintard et al., 2003; Pintard et al., 2004; Kwon et al.,
2006; Geyer et al., 2003; Cummings et al., 2009; Choi et al., 2016;
Chen et al., 2009), but previous work from our laboratory has shown
that Cul3 binds cyclin E in a yeast two-hybrid screen, indicating that
these proteins may interact directly with each other (Singer et al.,
1999). In order to determine the nature of the interaction between Cul3
and cyclin E, and whether the two proteins interact directly with each
other, several Cul3 mutants were co-transfected with cyclin E and their
binding was measured through immunoprecipitation assays. The
mutants represented disruptions of the major functional regions of
Cul3: the BTB domain interaction region (residues 51–67; Cul3Δ51-
67), the Nedd8 modification site (K712R), and the gain of function
403–459 deletion (Wimuttisuk et al., 2014; McCormick et al.,
2014; Wimuttisuk and Singer, 2007; Zheng et al., 2002; Boyden
et al., 2012). Cyclin E bound to all Cul3 mutants tested, including
the Cul3Δ51-67 mutant, which cannot bind BTB proteins
(Fig. 1A, lane 3). This finding is consistent with cyclin E being
able to bind directly to Cul3 without the aid of a BTB protein.
In order to further delineate the interaction between Cul3 and
cyclin E, Cul3 and cyclin E binding was examined in the presence of
SPOP, a BTB protein that targets other (non-cyclin E) Cul3
substrates for ubiquitylation (Kwon et al., 2006; Zhang et al., 2014).
First, we compared the ability of cyclin E to bind SPOP in
comparison to RhoBTB3 as a control, because RhoBTB3 has been
shown to bind cyclin E (Lu and Pfeffer, 2013) (Fig. 1B). We
determined that cyclin E associates with SPOP only in the presence
of Cul3, whereas cyclin E binds to RhoBTB3 under all
circumstances tested (Fig. 1B, compare lanes 3 and 5 to lanes 2
and 4). These data suggest that the observed interaction between
cyclin E and SPOP can only occur if it is mediated by Cul3
(Fig. 1B). To further analyze this relationship, cyclin E and SPOP
were co-transfected with wild-type (WT) Cul3 and we observed, as
shown in Fig. 1C, that cyclin E can co-immunoprecipitate SPOP;
however, cyclin E was not able to co-immunoprecipitate SPOP
when the Cul3 mutant Cul3Δ51-67, which cannot bind BTB
domain-containing proteins, was used (Fig. 1C, lane 2 compared to
lane 3). These data demonstrate that Cul3 can link cyclin E to SPOP
as immunoprecipitation of SPOP by cyclin E occurs only when
SPOP is bound to Cul3. These data support the hypothesis that a
direct interaction occurs between cyclin E and Cul3 and also
indicate that the interaction between Cul3 and cyclin E occurs
outside of the BTB-binding region on Cul3.
Mutations in the N-terminal region of cyclin E prevent
degradation by the Cul3 complex
Tomore precisely map the region of cyclin E that binds to Cul3, two
C-terminally truncated cyclin E mutants were analyzed for binding
to Cul3 and compared to full-length cyclin E. These consisted of the
N-terminal 200 amino acids (STOP 200) of cyclin E and the
N-terminal 300 amino acids (STOP 300) of cyclin E (Fig. 2A). A
STOP 100 truncation of cyclin E was also transfected, but it was
found to be unstable and therefore not used for further
experimentation (Fig. 2A). Cul3 bound to both cyclin E truncation
mutants as well as WT cyclin E (Fig. 2B, compare lanes 2 and 4 to
lane 6), indicating that Cul3 interacts with the N-terminal half of
cyclin E. To further pinpoint the binding site, we examined the
potential binding of several cyclin E alanine-scanning mutants to
Cul3 (Kelly et al., 1998). Each mutant in this set contains a charged
amino acid sequence that has been mutated to alanine residues
(Fig. 2C). Among the set of mutants, one alanine-scanning mutant
(DPDEE→AAAAA; amino acids 41–45), which is located near the
N-terminus, showed decreased binding to Cul3 (Fig. 2D, first panel
lane 4 in comparison to lanes 2, 6 and 8).
After determining that Cul3 only requires the N-terminal portion of
cyclin E for binding, we sought to ascertain whether this region
contains all the necessary signals for Cul3-mediated degradation to
occur. To efficiently identify the precise interaction region, we
utilized a novel transfection assay that we developed using cells that
are deficient for Cul3. Cul3 is responsible for the differences in cyclin
E protein abundance between WT mouse embryonic fibroblasts
(MEFs) and cells deficient for Cul3, aswe have previously shown that
both cell types express similar levels of cyclin E mRNA (McEvoy
et al., 2007). It was observed that in Cul3 hypomorphic (floxed)
MEFs, transfected cyclin E was more abundant than in WT MEFs,
similar to the endogenous levels of cyclin E (McEvoy et al., 2007).
When transfected into the same cells, controls that are not Cul3
substrates express at the same levels in these cell types. The same
regulation of cyclin E was observed when comparing WT (Cul3
containing) and Cul3 knockout (KO) HEK293 cells (hereafter
denoted 293 cells) (Ibeawuchi et al., 2015) (Fig. 3A, lanes 1 and 2).
We reasoned that if a mutant cyclin E that lacked the Cul3 degronwas
transfected into these two genotypes, wewould not see a difference in
levels of cyclin E protein. By contrast, transfected cyclin E mutants
that are Cul3 substrates would be expected to express at higher levels
in the Cul3 KO cells than in WT 293 cells.
Two controls, WT cyclin E and lysine-lacking cyclin E, were
transfected into the two cell types (WT and Cul3 KO 293 cells). As
mentioned above, we observed that when transfected with equal
amounts of WT cyclin E, the protein was detected at higher levels in
the KO 293 cells than theWT cells (Fig. 3A, compare lanes 1 and 2).
In contrast, lysine-lacking cyclin E was expressed evenly in both
cell types (Fig. 3A, lanes 3 and 4), indicating the utility of this assay
as a measure of the substrate being recognized for degradation
instead of merely binding. To demonstrate that loss of degradation
causes an increase in transfected cyclin E protein abundance, WT
cyclin E was transfected in the presence and absence of the
proteasome inhibitor MG132 (Fig. S1). We observed that the level
of transfected cyclin E in the WT 293 cells increases in the presence
of MG132 (Fig. S1).
The relative steady-state levels of the cyclin E truncations were
examined by transfection into WT and Cul3 KO 293 cells. We
observed that both the STOP 200 and STOP 300 cyclin E
truncations are more abundant in the KO cells, implying that the
degron recognized by Cul3 is within the first half of the cyclin E
protein and that the C-terminal PEST sequence (residues 385–401)
is not necessary for Cul3-mediated degradation to occur (Fig. 3B,
compare lane 1 to lane 2 and compare lane 3 to lane 4). Taken
together, these results demonstrate that the Cul3 degron resides in
the N-terminal half of the cyclin.
To further establish the important role of the cyclin E N-terminal
domain (residues 1–86) in cyclin E ubiquitylation by Cul3, a Flag-
tagged fusion protein containing residues 2–86 of cyclin E was
fused to YFP. We observed that the fusion protein is only
ubiquitylated when both Cul3 and ubiquitin are present (Fig. 3C,
compare lane 4 to lanes 1 through 3). Conversely, WT YFP is not
ubiquitylated in this assay (Fig. 3C, lanes 5 through 8), thereby
demonstrating the specificity of the interaction between Cul3 and
the N-terminal portion of cyclin E, while clearly indicating that the
cyclin E N-terminal region alone contains the signals necessary for
Cul3-mediated ubiquitylation to occur.
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K48 on cyclin E is located in a newly identified degron and
serves as a ubiquitylation site for Cul3
To pinpoint specific residues on cyclin E that may be involved in
degradation, cyclin E alanine-scanning mutants were transfected
into the Cul3 WT and KO 293 cells (Kelly et al., 1998). Three
alanine-scanning mutants, DPDEE→AAAAA (residues 41–45),
KIDR→AIAA (residues 48–51), and DKED→AAAA (residues
79–82), showed similar levels of protein expression in the WT cells
Fig. 1. Cul3 directly binds cyclin E. (A) HEK293 cells were co-transfected with Myc–cyclin E1 and different Flag-tagged WT Cul3 or Cul3 mutants,
including Cul3Δ51-67, Cul3Δ403-459 and Cul3K712R or no construct (-). Immunoprecipitations (IPs) were performed using a Flag antibody. Awestern blot (WB)
using anti-cyclin E antibody was performed to detect transfected cyclin E (top panel). Controls for the original protein levels in the lysates are shown in the middle
two panels. (B) Myc–cyclin E was co-transfected with S-tag–RhoBTB3 (lanes 2 and 4) or S-tag–SPOP (lanes 3 and 5), with Flag–Cul3 in lanes 4 and 5. IPs were
performed using a polyclonal Myc antibody. IP results are shown in the top panel. The lower three panels show the original protein levels in the lysates.
(C) HEK293 cells were co-transfected with Flag–Cul3 or Flag–Cul3Δ51-67 and Myc–cyclin E, HA–ubiquitin and S-tag–SPOP. An IP for Myc–cyclin E was
performed followed by western blotting to detect S-SPOP (C, top panel) and Flag-Cul3 (C, second panel). The lower three panels show the original protein
levels of the lysates prior to IP. For all western blots, the migration of size markers is indicated on the sides of the gel images (kDa).
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compared to Cul3 KO cells, which suggests that they are not as
easily targeted for degradation by Cul3 as WT cyclin E (Fig. 3D,
DPDEE is shown in lanes 1 and 2, KIDR in lanes 3 and 4, and
DKED in lanes 5 and 6;WT cyclin E is shown in Fig. 3A lanes 1 and
2 for comparison). All three of these mutants are located near the
N-terminus of cyclin E. In order to further characterize the
importance of this region for Cul3-mediated degradation to occur,
two Myc-tagged constructs containing deletions in this region were
created (Fig. 3E). The first construct, cyclin EΔ31-82, is missing the
region encompassing the three alanine-scanning mutants that
demonstrated increased abundance. The second cyclin E deletion
construct, cyclin EΔ2-86, was designed to resemble the LMM cyclin
E found in some cancer cells and is missing the entire N-terminal
region (Fig. 3E). These mutants both expressed at similar levels in
WT cells and Cul3 KO cells (Fig. 3F, compare lane 1 to 2, and lane 3
to lane 4), suggesting that residues 31 through 82 on cyclin E are
necessary for Cul3-mediated degradation of cyclin E to occur.
Changes in abundance exhibited by mutant proteins can often be
explained by changes in the location of the protein within the cell. In
order to determine whether the phenotypes of the three stable
Fig. 2. The N-terminal domain of cyclin
E is required for binding to Cul3.
(A) A cartoon showing full-length WT
cyclin E (top) and three truncation mutants
of the protein, STOP 100, STOP 200 and
STOP 300. (B) HEK293 cells were
transfected with constructs as indicated.
Upper blot, immunoprecipitation (IP) for
Flag–Cul3 and western blot (WB) for
Myc–cyclin E showing binding. Middle two
blots show relative levels of transfected
protein in cell extracts and the lower panel
shows the Flag blot of the Flag IP. (C)
Cartoon depicting the locations of point
mutants and alanine-scanning mutants
(designated here by the first mutated
amino acid number) on cyclin E. The
cleavage site which produces LMM cyclin
E is shown in red. (D) HEK293 cells were
transfected with constructs as indicated.
Upper blot, IP for Flag-Cul3 and western
blot for Myc–cyclin E showing binding of
three N-terminally located alanine-
scanning mutants (lanes 4, 6, and 8) in
comparison to WT cyclin E (lane 2). The
middle two blots show levels of transfected
protein in the cell extracts. The lower panel
shows the Flag blot of the Flag IP. For all
western blots, the migration of size
markers is indicated on the sides of the gel
images (kDa).
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alanine-scanning mutants are the result of localization changes,
HeLa cells were transfected with each construct and visualized
using immunofluorescence microscopy. The cellular localization of
the three mutants was found to be predominantly nuclear, similar to
WT cyclin E, indicating that their increased abundance is not caused
by mis-localization (Fig. S2).
Fig. 3. The cyclin E N-terminal domain regulates cyclin E stability in the presence of Cul3. (A) Myc-tagged WT cyclin E was transfected into Cul3 KO
and WT HEK293 cells. There is a difference in the level of cyclin E between these two cells types, as indicated by western blotting (WB; left panel). Levels of a
transfected cyclin Emutant without lysine resides (lysineless), which cannot be ubiquitylated, are shown in the right panel. (B)Myc-tagged STOP200 andSTOP300
truncations of cyclin E were transfected into WT and Cul3 KO 293 cells and their expression level was assessed using a Myc (cyclin E) antibody. (C) Ubiquitylation
assay for the cyclin E residues 2–86 and YFP fusion protein. Cells were transfected with either Flag-tagged cyclin E–YFP (Flag-E-YFP) or Flag-tagged YFP
in the presence and absence of S-tag–ubiquitin and Flag–Cul3. Lysates were harvested and analyzed via immunoprecipitation (IP; Flag) and western blotting. Top
panel: results of the ubiquitylation assay. The cyclin E–YFP fusion protein is shown in lanes 1 through 4 and WT YFP is shown in lanes 5 through 8. Middle three
panels, western blots showing the total amount of protein in each lysate prior to the IPs. Lower panel, long exposure of the ubiquitylation assay. (D) ThreeMyc-tagged
alanine-scanning mutants, DPDEE→AAAAA (residues 41–45, lanes 1 and 2), KIDR→AIAA (amino acids 48–51, lanes 3 and 4) and DKED→AAAA (amino acids
79–82, lanes 5 and 6), were transfected into both WT and Cul3 KO HEK293 cells and their abundance was measured using an anti-Myc (cyclin E) antibody.
(E) Diagram showing two mutants in which portions of the N-terminal domain had been deleted. (F) Expression of transfected Myc–cyclin EΔ31-82 and Myc–cyclin
EΔ2-86 are shown in both theWTand KO cells (lanes 1 through 4). For A, B, D and E, quantification of the presented western blot (WB) is listed below each lane as a
percentage relative to the sample in the KO lane foreach pair. For all western blots, themigration of sizemarkers is indicated on the sides of the gel images (kDa). The
blots shown are representative of n=2 (A,B) or n=3 (D,E).
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The DPDEE→AAAAA (residues 41–45) mutant cannot bind
Cul3 as well as other cyclin E constructs (Fig. 2D), which could
provide a partial explanation for its increased protein levels in our
assay. The other two mutants, KIDR→AIAA (residues 48-51) and
DKED→AAAA (residues 79–82) both contain lysine residues
(Fig. 3D). The increased protein levels of these alanine-scanning
mutants as well as cyclin EΔ31-82 imply that both lysine residues
K48 and K80 are potential ubiquitylation sites, and the degron that
is recognized by Cul3 likely resides within the region spanned by
the cyclin EΔ31-82 deletion.
To establish whether ubiquitylation on K48 or K80 of cyclin E
regulates its relative expression levels, we determined whether the
alanine-scanning mutants were stabilized by a dominant-negative
mutation in ubiquitin that prevents K48 branching (K48R), a type of
branching that leads to degradation (Raasi and Pickart, 2005). We
have shown that this ubiquitin mutation results in stabilization of
cyclin E whereas a mutation in another important lysine in
ubiquitin, K63, has no effect (Fig. S3). To examine this, all of the
alanine-scanning mutants within the first 200 amino acids of cyclin
E were transfected into both cell types in the presence or absence of
a mutant K48R ubiquitin. We observed that, unlike WT cyclin E,
which was stabilized in WT cells by the addition of the dominant-
negative K48R ubiquitin mutant (Fig. 4A, compare lanes 1 and 2 to
lanes 3 and 4), the KIDR (48–51)→AIAA mutant was unaffected,
indicating it is no longer a substrate for ubiquitylation-dependent
degradation (Fig. 4A, lanes 13–16). The DPDEE (41–
45)→AAAAA (Fig. 4A, lanes 9–12) mutant behaved similarly to
the KIDR (48–51)→AIAA mutant. The DKED (79–82)→AAAA
mutant (Fig. 4A, lanes 17–20) appears similar to WT (Fig. 4A, top
left panel, lanes 1–4) in this assay, suggesting K48 (the KIDR
lysine) and not K80 (the DKED lysine) is the ubiquitylation site for
Cul3. As a second control, cyclin E T395A, which cannot be
degraded by Cul1, was examined, and we observed that it is a
substrate of Cul3, which demonstrates the specificity of our assay
(Fig. 4A, lanes 5–8). In order to confirm that K48 is a ubiquitylation
site on cyclin E, a point mutant, cyclin E K48R, was constructed for
use in the ubiquitylation assay. Like the KIDR (48–51) alanine-
scanning mutant, cyclin E K48R is more stable inWT cells thanWT
cyclin E (Fig. 4A, lanes 21 through 24), suggesting that K48 on
cyclin E is indeed a ubiquitylation site utilized by Cul3 in vivo.
These data suggest the presence of a Cul3 degron on cyclin E
located near the cyclin E N-terminus. The residues DPDEE (41–45)
and KIDR (48–51) constitute the Cul3 binding site (DPDEE) and
the ubiquitylation site (KIDR) utilized by Cul3 to target cyclin E for
ubiquitin-mediated proteolysis.
Previous work from our laboratory has shown that Cul3
regulates endogenous cyclin E, as WT cyclin E has a longer
half-life in cells that are deficient for Cul3 and this longer half-life
is not associated with changes in mRNA levels of either cyclin E1
or cyclin E2 (McEvoy et al., 2007). To determine whether cyclin E
K48R is differentially degraded by Cul3 as compared toWT cyclin
E, we measured the half-life of these proteins in cells of both
genotypes (Cul3 WT and KO). Cells were transfected with full-
length Myc-tagged WT cyclin E or Myc-tagged cyclin E K48R.
Following addition of cycloheximide (CHX) the cells were
harvested every 2 h for 8 h. We observed that WT cyclin E has a
short half-life in the WT cell line but a dramatically increased half-
life in the KO cells, demonstrating that loss of Cul3 increases the
half-life of cyclin E [Fig. 4B, compare WT cyclin E in WT cells
(top left), and WT cyclin E in KO cells (bottom left)]. Next, we
measured the half-life of the cyclin E mutant K48R, the putative
ubiquitylation site. Cyclin E K48R had a half-life longer than WT
cyclin E in bothWT and Cul3 KO cells, demonstrating that K48 on
cyclin E is required for Cul3-mediated degradation to occur
[Fig. 4B,C, compare the half-life of WT cyclin E (Fig. 4B) to
cyclin E K48R (Fig. 4C)].
TheN-terminaldomainofcyclinE is required forCul3-mediated
degradation
As LMM cyclin E can be found endogenously in some cells, we
sought to determine whether loss of Cul3 affects the presence of
these LMM forms. Overall, the Cul3 KO 293 cells have more
endogenous cyclin E than the WT (Ibeawuchi et al., 2015). We
observed that the 50 kDa endogenous cyclin E band increases upon
inhibition of the proteasome in WT cells to equal the amount of the
50 kDa protein that is present in the KO cells prior to proteasome
inhibition, demonstrating that the 50 kDa band is a substrate of Cul3
in 293 cells (Fig. 5A, lane 2 vs lane 3). Two LMM cyclin E bands
are also detected, the smallest of which is ∼43 kDa. These two
LMM cyclin E bands are present in bothWT and KO cells (Fig. 5A).
The relative abundance of the LMM bands is elevated equally in
both cell types upon proteasome inhibition (Fig. 5A, lanes 2 and 4),
indicating that LMM cyclin E is targeted for ubiquitin-mediated
proteolysis equally in both cell types.
Next, to determine whether the rate of degradation of LMM
cyclin E is impacted by Cul3, Myc-tagged cyclin EΔ2-86, which
lacks the N-terminal domain, was transfected into WT and Cul3 KO
293 cells. CHX was added to the samples and time points were
collected every 2 h over the course of 10 h (Fig. 5B). The results of
this experiment shows that cyclin EΔ2-86 has the same half-life in
WT and KO cells, demonstrating that Cul3 is unable to regulate the
abundance of cyclin E protein that lacks its N-terminal domain
(Fig. 5B). To further test the role of this degron in Cul3-mediated
degradation, we created a YFP fusion protein which contains
residues 2 through 86 (the N-terminal region) of cyclin E fused to a
Flag-tagged YFP. This cyclin E–YFP fusion protein has a shorter
half-life than YFP alone in WT cells but not in the Cul3 KO cells,
consistent with our previous conclusion that the N-terminal domain
of cyclin E contains the signals necessary for degradation
(Fig. S4A). In addition, Cul3 can bind the YFP-containing protein
that contains the Cul3 degron but cannot bind YFP alone (Fig. S4B).
These results are consistent with our above data demonstrating the
importance of K48, which is located in the N-terminal region, for
Cul3-mediated degradation of cyclin E. Together, these data suggest
that Cul3 is unable to regulate the LMM truncated forms of cyclin E
that occur in vivo and lack the Cul3 degron. LMM cyclin E has been
shown to bind Cdk2 and results in increased Cdk2 activity (Porter
et al., 2001; Wingate et al., 2005). Our data indicate that LMM
cyclin E is not a Cul3 substrate, providing a possible mechanism that
LMM cyclin E1 might employ in order to bypass ubiquitylation by
the Cul3 pathway, thereby increasing its availability to bind Cdk2
(Fig. 5C).
Cyclin E2 lacks the Cul3 degron and is not targeted for
degradation by Cul3
The structure of cyclin E bound to Cdk2 has been determined
(Honda et al., 2005), but the published structure only includes
amino acids 81–363 of cyclin E, omitting the N-terminal region.
Recently, advanced modeling techniques have predicted a structure
for the N-terminal region of cyclin E that shows that this
portion of the protein is mostly disordered with the notable
exception of a predicted α-helix encompassing the sequence
DEEMAKID (residues 43–50, Fig. 6A) (Rath and Senapati,
2014). Coincidentally, the alanine scanning mutants located
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within this proposed helix [DPDEE (41–45)→AAAAA and KIDR
(48–51)→AIAA] exhibited the most notable phenotypes in our
study as DPDEE (41–45) exhibited diminished binding to the Cul3
complex and KIDR (48–51)→AIAA cannot be degraded in a Cul3-
dependent manner (Figs 2D, 4 and 6). Our data suggest that this
structural motif may form part of the interface on cyclin E that is
Fig. 4. Cul3-mediated ubiquitylation of cyclin E on K48 regulates cyclin E abundance. (A) Alanine-scanning and point mutants located within the
first 200 amino acids of the cyclin E protein were transfected in Cul3 WT and KO 293 cells in the presence or absence of an S-tagged K48R ubiquitin construct.
Wild-type cyclin E (lanes 1-4) and cyclin E T395A, which cannot be degraded by Cul1 (lanes 5–8), were included as controls. Three cyclin E alanine-scanning
mutants are shown here, DPDEE→AAAAA (residues 41–45, lanes 9–12), KIDR→AIAA (residues 48–51, lanes 13–16), and DKED→AAAA (residues 79–82,
lanes 17–20). The point mutant cyclin E K48R is also shown (lanes 21–24). The total amount of protein in each lane was quantified for the blot shown and is
presented as a percentage relative to that in the knockout lane. (B,C) Cul3 WT and KO 293 cells were transfected with Myc-tagged cyclin E (B) or Myc-tagged
cyclin E K48R (C). After 24 h, CHX was added, and cells were harvested at the indicated time points. Half-lives were determined via western blotting (top), and
quantified (for the blot shown, bottom). For all western blots, the migration of size markers is indicated on the sides of the gel images (kDa). The blots shown are
representative of n=2 (A, lanes 1–20, B,C) or n=1 (A, lanes 21–24).
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responsible for Cul3 interaction and also functions as the Cul3
degron on cyclin E (Fig. 6A). The putative helix comprising the
Cul3 degron, including the K48 ubiquitylation site, is conserved in
rodents (Fig. 6B), which is notable as Cul3 also regulates cyclin E in
mice (Singer et al., 1999; McEvoy et al., 2007).
Mammals contain two cyclin E-encoding genes,CCNE1 (cyclin
E1) and CCNE2 (cyclin E2), which produce different proteins
(Sherr and Roberts, 1999; Geng et al., 2003). The two cyclin E
proteins share a high degree of similarity and many structural
similarities, including the Cdk2-interacting domain (Zariwala
et al., 1998). To determine whether both cyclin E proteins contain
the proposed Cul3 degron, we analyzed the net charge of the
region by calculating the difference between the number of basic
residues and the number of acidic residues and ascertained that the
cyclin E1 degron is acidic with a net charge of negative two. The
corresponding region on cyclin E2, in contrast, is extremely
basic with a net charge of plus four (Fig. 6C). A Chou–Fasman
algorithm was used to predict possible structures of both cyclin E
proteins in the degron region (Chou and Fasman, 1975). This
method predicts structural differences in the proposed degron
region between the two proteins, revealing what is possibly a
helical region in cyclin E1 is potentially an unstructured region in
cyclin E2 (Fig. 6C, ‘h’ indicates helix and ‘n’ indicates no
predicted structure). Taken together, this information suggests that
the Cul3 degron comprises a structural feature that is unique to
cyclin E1.
Next, to determine whether the observed Cul3-mediated
degradation of cyclin E is specific to cyclin E1, cyclin E2 was
transfected into the WT and KO 293 cells. Cyclin E2 was expressed
evenly in both cell types, indicating that it does not get degraded by
a Cul3-dependent mechanism (Fig. 6D, lanes 1 and 3 compared to
lanes 2 and 4), and unlike cyclin E1, cyclin E2 did not bind Cul3 in
an immunoprecipitation assay (Fig. 6E). Finally, transfected cyclin
E2 has a similar half-life in the WT and KO 293 cells, suggesting
that it is not a Cul3 substrate (Fig. S5). Together, these data suggest
that Cul3 selectively targets cyclin E1 for Cul3-mediated
degradation.
Loss of Cul3 results in early accumulation of cyclin E after
release from serum starvation
The Cul1 E3 ligase also targets cyclin E for degradation and does so
in a distinct window in the cell cycle, beginning at ∼4 h after the
Fig. 5. LMM cyclin E is not degraded by Cul3. (A) The upper blot shows levels of endogenous cyclin E in WT and Cul3 KO 293 cells. The proteasome
inhibitor MG132 has been added to the cells shown in lanes 2 and 4. The lower blot shows levels of actin in the same cells. (B) WT and Cul3 KO 293 cells were
transfected with cyclin EΔ2-86. CHX was added at 24 h post transfection and cells were harvested every 2 h following CHX addition. Top panel, western blots
showing protein levels. Lower panel, quantification of results for blot shown (representative of n=2). (C) Model showing full-length cyclin E being ubiquitylated
and degraded via a Cul3-mediated process during G1, leaving some cyclin E available to activate Cdk2 (top). In cells containing LMM cyclin E, which lacks its
N-terminal domain, correct ubiquitylation by Cul3 might not occur, possibly contributing to increased activation of Cdk2. For all western blots, the migration of
size markers is indicated on the sides of the gel images (kDa).
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onset of DNA replication (Bhaskaran et al., 2013). In order to
ascertain when during the cell cycle loss of Cul3 results in cyclin E
accumulation, we turned to the Cul3 KO 293 cells. Previous work
from our laboratory has shown that loss of Cul3 in MEFs results in
increased amounts of cyclin E and a greater percentage of cells in S
phase (McEvoy et al., 2007). Similarly, analysis of Cul3 KO 293
cells by flow cytometry showed an increased percentage of cells in S
phase when compared to WT 293 cells (Fig. 7A). The observed
increase in Cul3 KO cells undergoing DNA replication indicates
that the excess cyclin E in the Cul3 KO 293 cells promotes entrance
into S phase. To determine at what time during the cell cycle the
Cul3 KO cells begin to accumulate excess cyclin E, both WT and
KO cells were synchronized in G1 via serum starvation and released.
The results of this experiment shows that KO cells enter S phase
earlier than their WT counterparts, as by 4 h after release into G1,
only 47.1% of synchronized WT cells are in S phase or G2 but
61.7% of Cul3 KO cells have reached this point (Fig. 7B, WT cells
are shown on the left and KO are shown on the right).
To determine whether the early entrance of the KO cells into S
phase is a result of cyclin E accumulation during G1, we examined
cyclin E accumulation in Cul3 hypomorphic MEFs after serum
starvation and release. Cyclin E protein accumulated to significant
levels 2 h earlier in Cul3 hypomorphic (floxed) MEFs than in WT
MEFs (Fig. 7C WT, top row, Cul3 hypomorphic flx/flx, middle
row). Similarly, cyclin E–Cdk2 kinase activity is also elevated prior
to S phase in Cul3 KO 293 cells (Fig. 7C, bottom panel). This is
consistent with a role for Cul3 in regulation of cyclin E levels in
non-cycling cells, as we had previously observed in an animal
model (McEvoy et al., 2007). The early entrance of the Cul3
hypomorphic cells into S phase suggests Cul3 regulation of cyclin E
occurs earlier than the Cul1-mediated regulation of cyclin E that
occurs during S phase (Bhaskaran et al., 2013).
DISCUSSION
Cyclin E protein accumulates in late G1, peaks in early S phase and
rapidly disappears. Increased levels of cyclin E are associated with
cell cycle errors, and loss of cyclin E in MEFs results in the inability
of the cells to exit from quiescence (Said and Medina, 1995; Geng
et al., 2003). Research has shown that cyclin E can be
proteolytically cleaved, resulting in truncated forms of the cyclin,
many of which lack portions of the protein near the N-terminus
(Wang et al., 2003; Porter et al., 2001). These LMM forms of cyclin
Fig. 6. Cyclin E1 contains a Cul3 degron that is absent in cyclin E2. (A) The proposed helix (A, represented by the red bar) overlaps the DPDEE (Cul3 binding)
and KIDR (ubiquitylation site) alanine-scanning mutants (shown in red). (B) The Cul3 degron is highly conserved in mouse (Mus musculus) and rat (Rattus
norvegicus) cyclin E1 (outlined in red). (C) Sequence comparison of the degron region in cyclin E1 (bottom) to the same region in cyclin E2 (top). Chou–Fasman
analysis of the amino acid sequences suggests that the structures differ between cyclin E1 and cyclin E2. Additionally, the Cul3 degron in cyclin E1 is acidic,
with a net charge of minus two (difference between the number of acidic residues and the number of basic residues). The same region in cyclin E2 is basic
with a net charge of plus four. (D)Western blots (WB) level of transfectedMyc-tagged cyclin E2, shown here in duplicate inWT (lanes 1 and 3) and Cul3 KO (lanes
2 and 4) HEK 293 cells. (E) Myc-taggedWT cyclin E1 (lanes 1 and 2), the 48–51 (KIDR) alanine-scanningmutant (lanes 3 and 4), andMyc–cyclin E2 (lanes 5 and
6) were transfected into HEK293 cells in the presence and absence of Flag–Cul3 and immunoprecipitated (IP) using an anti-Flag antibody. Upper blot:
Flag IP, Myc western blot showing the IP results. Lower blots: western blots showing protein expression levels. For all western blots, the migration of size markers
is indicated on the sides of the gel images (kDa).
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E are associated with poor prognosis in cancer patients and
overexpression of the LMM cyclin E has also been shown to cause
cell cycle errors including chromosome mis-segregation (Akli
et al., 2010; Duong et al., 2012; Bagheri-Yarmand et al., 2010).
Others have shown that these errors result from the increased
ability of LMM cyclin E to bind and activate Cdk2, which
increases Cdk2 kinase activity (Porter et al., 2001; Wingate et al.,
2005). Healthy cells rely upon degradation of cyclin E protein by
the ubiquitin–proteasome system in order to restrict levels of
cyclin E. The Cul3 E3 ligase targets cyclin E for degradation, and
our work sheds light upon the mechanism utilized by Cul3 to
ubiquitylate cyclin E.
Fig. 7. Cul3 regulates cyclin E degradation early during G1. (A) Flow cytometry analysis of proliferating 293 cells. WT cells are shown on the left and Cul3 KO
cells are shown on the right. Cells in G1 are shown in purple, S phase cells are shown in yellow, and G2/M cells are shown in green. The quantification shown
represents the mean±s.d. of three experiments. (B) Cells were serum-starved and released into G1. Cells were harvested at 4-h intervals, stained with propidium
iodide, and analyzed by flow cytometry. (C) Western blot showing levels of endogenous cyclin E in mouse embryonic fibroblasts (MEFs) that are
WT (WT, western blot, top row) or deficient for Cul3 (flx/flx, western blot, bottom row). Results of a kinase assay for cyclin E–Cdk2 activity in synchronized
HEK293 cells are shown in the graph beneath the western blot. Cells were synchronized in G1 and then released and harvested at the indicated time points.
Cyclin E and Cdk2 were purified from the lysates via immunoprecipitation and then used in a kinase assay which couples kinase activity to phosphate production.
Cells that had been serum-starved and released were collected at 2-h intervals as indicated. The plot is derived from one dataset; n=1, except for the 0 hour time
point where n=2. (D) These data are consistent with a model where Cul3 is responsible for maintaining cyclin E levels during G1 in order to prevent early entrance
into S phase. Cul1 is known to degrade cyclin E after S phase has begun.
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We have identified a Cul3 degron in cyclin E1 that spans the acidic
region between residues 41 and 51 (DPDEEMAKIDR), located near
the N-terminus of the cyclin. This degron consists of a region
involved in Cul3 binding (residues 41–45) and a ubiquitylated lysine
residue, K48. The N-terminal region containing the degron had not
been shown to be part of the core cyclin E protein and is not necessary
for Cdk2 activation to occur (Porter and Keyomarsi, 2000; Porter
et al., 2001). Our analysis, as well as those from other investigators,
suggest that this acidic region forms a structural motif within the
disordered N-terminal domain on cyclin E1 (Fig. 6A; Rath and
Senapati, 2014). In addition, we show that Cul3 uses this structural
feature, which is conserved in mammals (Fig. 6B), to recognize
cyclin E1 for ubiquitylation (Fig. 6). We demonstrate that the Cul3
degron is specific to cyclin E1, as the corresponding region in cyclin
E2 carries a positive (basic) charge (Fig. 6C) and levels of cyclin E2
are not affected by deletion of Cul3 (Fig. 6D; Fig. S5).
In addition, and surprisingly, mutation of the Cul3 degron on
cyclin E results in a stable cyclin E, implying that, in 293 cells, the
Cul3 pathway is the predominant pathway involved in the
degradation of cyclin E (Fig. 4A, lower right panel, Fig. 4C).
Mutation of K48 in cyclin E to an arginine residue (K48R) results in
stabilization of cyclin E, as this form has a longer half-life than WT
cyclin E, implying that K48 is the principal ubiquitylation site on
cyclin E utilized by Cul3 (Fig. 4A, lower right panel, Fig. 4C). The
longer half-life of cyclin E K48R in comparison to WT cyclin E has
been seen in multiple experiments (n=4), demonstrating
the significance of this result. Similarly, deletion of the cyclin E
N-terminus (cyclin EΔ2-86) prevents Cul3-mediated degradation of
cyclin E (Fig. 5B). The half-life of cyclin E1 that cannot be
ubiquitylated by Cul3 is longer than the half-life of WT cyclin E,
indicating the necessity for Cul3 in cyclin E regulation (Fig. 4B
compared to Figs 4C and 5B).
LMM cyclin E, which results from proteolytic processing and
often lacks portions of the N-terminal region, represents a
particularly active form of cyclin E that is made in cancer cells
and associated with tumorigenesis (Porter and Keyomarsi, 2000;
Keyomarsi et al., 1995; Bagheri-Yarmand et al., 2010; Akli et al.,
2004; Akli et al., 2010; Porter et al., 2001). Our data suggest that the
loss of the newly identified Cul3 degron may contribute to the
increased Cdk2 activity that is observed in cells containing LMM
cyclin E (Fig. 5C). We constructed a cyclin E deletion mutant,
cyclin EΔ2-86, that is missing the N-terminal region, similar to the
naturally occurring LMM cyclin E variants that lack the majority of
the N-terminal domain (Fig. 3E). Like cyclin E K48R, cyclin
EΔ2-86 is also more stable, suggesting that cyclin E1 that lacks the
degron cannot be targeted for degradation by Cul3 (Figs 3F and 5B).
This finding suggests that removal of the N-terminal cyclin E
degron allows for the bypassing of Cul3-mediated degradation of
LMM cyclin E1, resulting in more cyclin E being available to
interact with Cdk2 (Fig. 5C). Although LMM cyclin E1 is still a
substrate of the ubiquitin system (Delk et al., 2009), our results
suggest that it is unable to be degraded in a Cul3-dependent manner
(Fig. 5A). Levels of endogenous LMM cyclin E are increased upon
addition of MG132 in Cul3 KO 293 cells (Fig. 5A), which further
supports the idea that cyclin E lacking its N-terminal region is not a
Cul3 substrate (Fig. 5A–C).
In addition to clarifying the mechanistic details regarding Cul3-
mediated degradation of cyclin E1, the work presented here also
identifies the temporal window during which such degradation
occurs. Previous work has shown that loss of Cul3 results in cyclin
E accumulation and exit from quiescence in mice (McEvoy et al.,
2007), leading us to hypothesize that loss of Cul3 results in earlier
increases in cyclin E and entry into S phase. Here, this hypothesis is
supported, as cells that are hypomorphic for Cul3 both enter the cell
cycle earlier than their WT counterparts and show increased levels
of cyclin E and associated kinase activity earlier than WT cells
following release from serum starvation (Fig. 7B,C). These data
suggest that Cul3 is responsible for maintaining levels of cyclin E
early in the cell cycle, preceding the start of S phase, which is in
contrast to the Cul1 degradation pathway, which degrades cyclin E
later during S phase (Bhaskaran et al., 2013). Taken together, our
data suggest that during G1, Cul3 functions to suppress levels of
cyclin E via ubiquitylation of its N-terminal domain (Fig. 5B). Lack
of cyclin E regulation by Cul3 during G1 might contribute to the
increased cyclin E–Cdk2 activity that has been observed in cancer
cells containing LMM cyclin E (Figs 5C and 7D).
Finally, this study suggests that the mode of recognition of cyclin
E1 by Cul3 is unique, as it does not require a substrate adaptor. We
show that Cul3 binds cyclin E independently and outside of the
BTB-binding region (residues 51–67) on Cul3 (Fig. 1A,C),
suggesting that Cul3 does not require a BTB protein in order to
ubiquitylate cyclin E1. As other Cul3 substrates are known to
require BTB proteins to enhance binding to the Cul3 E3 ligase
complex (Zhang et al., 2004; Cummings et al., 2009), our finding
that cyclin E can bind Cul3 directly suggests that cyclin E is a unique
substrate of Cul3. A search of the literature revealed another Cul3
substrate, heat-shock factor 2 (HSF2), which is targeted for
degradation upon binding directly to Cul3 via two PEST
sequences (Xing et al., 2010). PEST sequences are defined as
acidic regions rich in the amino acids D, E, P, S and T that are
flanked by basic residues (Rogers et al., 1986). Our results show that
the C-terminal PEST sequence in cyclin E is not required for Cul3-
mediated degradation to occur (Fig. 3B); however, the degron that
we identified near the cyclin E N-terminus lies within a region that
also satisfies the definition of a PEST sequence (residues 31–51,
RKANVTVFLQDPDEEMAKIDR). This observation suggests that
a PEST motif facilitates ability of Cul3 to recognize cyclin E,
demonstrating similarity to the PEST motifs in HSF2 which
facilitate its ubiquitylation by Cul3 (Xing et al., 2010). Together,
this information suggests a newmode of cullin substrate recognition
whereby Cul3 binds some substrates without the aid of a BTB
domain-containing protein. This idea will merit further study to
determine what, if any, role BTB proteins might play in instances
where Cul3 is responsible for substrate recognition. Others have
suggested that the BTB protein RhoBTB3 is involved in cyclin E
degradation and knockdown of RhoBTB3 resulted in elevated
levels of cyclin E and increased proliferation (Lu and Pfeffer, 2013),
which suggests to us that RhoBTB3might play a non-canonical role
in cyclin E ubiquitylation.
MATERIALS AND METHODS
Cell culture and transfections
Cells [HeLa, ATCC CCL-2; HEK 293, ATCC CRL-1573; MEFs, our
laboratory source, McEvoy et al. (2007)] were maintained in DMEM
supplemented with 10% fetal bovine serum and penicillin-streptomycin.
HEK 293 and HeLa cells were split 1:20 for transfection in 6 cm dishes the
night before transfection. Transfections were performed using the calcium
phosphate precipitation method. For immunoprecipitations and expression
level assays, cells were harvested 48 h post transfection. For HeLa and 293
cells, between 1 and 10 μg of plasmid DNAwas transfected into each plate.
For experiments utilizing MG132 (Sigma-Aldrich), the drug was added
∼18 h before harvest at a final concentration of 20 μM. All transfections
were harvested using RIPA buffer supplemented with protease inhibitors
and then sonicated before being used for immunoprecipitations or western
blotting.
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All Cul3 mutants (Cul3 K712R, Cul3Δ51-67, and Cul3Δ403-459) were
expressed using the same p3x-Flag vector (Sigma) as was WT Cul3. Cyclin
E mutants were expressed using the CS2+ Myc-tagged expression vector,
and a CS2+ S-tagged vector was used for the expression of SPOP.
The pCMV3-tag-6 vector (Agilent) was used for construction of the cyclin
E–YFP fusion protein shown in Fig. 3C and Fig. S4.
Western blotting and immunoprecipitations
Western blots and immunoprecipitations were conducted as previously
described (Wimuttisuk et al., 2014). In short, a sonicated transfection lysate
was added to the desired antibody in an Eppendorf tube and brought to a
final volume of 500 μl. 40 μl of IPA–Sepharose beads were then added to
the mixture, and the immunoprecipitations were placed on a rotator for 2 h at
room temperature before being rinsed with RIPA buffer, heated in SDS-
loading buffer, and run on an SDS-PAGE gel. The following antibodies
were used for immunoprecipitations at 1–2 μg or at the indicated dilution for
western blotting: monoclonal anti-FLAG (1:1000, cat. number F3165, Sigma-
Aldrich), monoclonal anti-Myc (9E10) (1:500, c-Myc mouse anti-Human,
cat. number MA1-980, Invitrogen), polyclonal anti-c-Myc (A14) (1:500,
Santa Cruz Biotechnology), S-peptide monoclonal antibody (1:1000, clone
6.2, cat. number MA1-981, Invitrogen), monoclonal anti-HA.11 (16B12)
(1:1000, cat. number: MMS-101P-200, BioLegend), polyclonal anti-HA
(1:1000, cat. number PA1-985, Invitrogen), polyclonal anti-β actin
(cat. number AM4302, Invitrogen), polyclonal anti-cyclin E (1:500 for
endogenous cyclin E, 1:1000 for transfected samples, Singer et al., 1999),
polyclonal anti-Cul3 (Singer et al., 1999;McEvoy et al., 2007), andmonoclonal
anti-cyclin E (HE12) (1:500 for endogenous protein, 1:100 for transfected
samples, cat. number 32-160-0, Invitrogen).
Half-life determination
For experiments using CHX (Sigma-Aldrich), cells were transfected as
described and the drug was added 24 h post-transfection at a final
concentration of 50 μg/ml. Cells were then harvested at the time points
indicated. Quantification of the western blots for all CHX experiments was
done using the FluorChem SP software (Alpha Innotech) or ImageJ (National
Institutes of Health) and graphs were generated using Microsoft Excel.
Immunofluorescence
HeLa cells were grown on coverslips, transfected, followed by incubation in
4% paraformaldehyde/PBS at room temperature for 10 min. Cells were then
permeabilized using a solution of 1% Triton X-100 with 2 mM EGTA and
5 mM PIPES, followed by incubation in methanol at −20°C for 10 min.
Cells were then rinsed with PBS and stained overnight with a polyclonal
Myc antibody (1:600, A14, Santa Cruz Biotechnology). The next day, cells
were rinsed and stained with an Alexa Fluor 488-conjugated secondary
antibody (Abcam) followed by DAPI, rinsed in methanol, and mounted on
coverslips for viewing. Microscopy was conducted using a Zeiss M2
microscope and AxioVision software.
Flow cytometry
Proliferating cells were harvested when they were 70% confluent. Cells were
resuspended in 70% ethanol in PBS and stored at 4°C until analysis. Prior to
analysis, fixed cells were stained in a solution of propidium iodide in PBS
with RNase A at 37° for a minimum of 30 min. Cells were then strained and
analyzed on a BD Accuri C6 benchtop flow cytometer (BD). Three
proliferating samples of each genotype were analyzed and 20,000–50,000
cells were counted for each sample. Analysis shown in Fig. 7A was
completed using FlowJo software (TreeStar).
Kinase assays
Cells were harvested in RIPA and lysed. Proliferating cells were harvested
between 50% and 75% confluence and synchronized cells were serum-
starved for 24 h and then harvested at 2-h intervals following release into the
cell cycle. Cell lysates were incubated in the polyclonal anti-cyclin E
antibody (1:100) overnight on a rotator at 4°C. The next morning, Sepharose
beads were added to the lysates and they were incubated for an additional
hour and a half at room temperature. Beads were precipitated on ice and the
supernatant was removed, followed by two washes with RIPA and two
washed with histone wash buffer (25 mM Tris-HCl pH 7.5, 70 mM NaCl,
10 mM MgCl2 and 1 mM dithiolthreitol). Kinase reactions were then
completed in the microcentrifuge tubes containing the kinase and beads
according to the protocol provided with the Universal Kinase Activity Kit
(R&D Systems, product number EA004). Following the final incubation,
the liquid contents of each tube were transferred to a 96-well plate and the
absorbance was read at 630 nm on a BioTek Synergy HT plate reader. Data
were analyzed using Microsoft Excel.
Construction of cyclin E mutants
The majority of the alanine-scanning mutants were a kind gift from Jim
Roberts at the Fred Hutchinson Cancer Center (Kelly et al., 1998). The point
mutants were made using site-directed mutagenesis and all point mutants
were confirmed by sequencing. The sequence of alanine-scanning mutants
that demonstrated a phenotype were also re-confirmed. Truncations were
cloned by using mutagenesis to generate a stop codon at the designated
location in the cyclin E protein. Both deletions were made using site-
directed mutagenesis and were also confirmed by sequencing. Forward
primer sequences for mutagenesis are as follows: cyclin EΔ2-86 5′-GGA-
CTTGAATTCCATGGTTTACCCAAACTCAA-3′, cyclin E KIDR point
mutant (K48R) 5′-CGCCGTCCTGTCGATTCTGGCCATTTCTTCAT-3′,
cyclin EΔ31-82 5′-GCTCGCTCCAGGAAGGATGACCGGGTTTAC-3′.
Primer sequences for the cyclin E truncations are as follows: Cyclin E STOP
200 5′-TCATCTTTATTTATTTGAGCCAAACTTGAGGAA-3′, and ST-
OP 300 5′-TTTCCTTATGGTATATGAGCTGCTTCGGCCTGG-3′. All
reverse primers were reverse complements of the forward primers. The
control YFP fusion protein construct was made by cloning YFP in frame
with a Flag tag into the pCMV-3Tag-6 vector. The cyclin E–YFP fusion was
then constructed by cloning residues 2–86 of cyclin E in between the Flag
tag and YFP.
Chou–Fasman structure prediction
The Chou–Fasman algorithmwas used for the structural prediction shown in
Fig. 6C (Chou and Fasman, 1975).
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